The combined treatment of amyloid-β1-42-stimulated bone marrow-derived dendritic cells plus splenocytes from young mice prevents the development of Alzheimer's disease in APPswe/PSENldE9 mice

Neurobiology of Aging

Volumn 36, Issue 1, 2015, Pages 111-122

  Wang, Fei ^a   Liu, Hanqiu ^b   Shen, Xueyan ^a   Ao, Hong ^c   Moore, Nick ^d   Gao, Lingling ^a   Chen, Long ^a   Hu, Heng ^a   Ma, Huiying ^a   Yang, Zixiao ^a   Zhai, Chunxiao ^a   Qin, Jie ^a   Zhou, Guomin ^a   Peng, Yuwen ^a   Feng, Xiaoyuan ^b   Li, Ruixi ^a   Liang, Chunmin ^a  

^a FUDAN UNIVERSITY   (China)

^b FUDAN UNIVERSITY   (China)

^c FUDAN UNIVERSITY   (China)

^d HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Alzheimer's disease; Bone marrow derived dendritic cell; Immune senescence; Immunotherapy

Indexed keywords

AMYLOID BETA PROTEIN ANTIBODY; AMYLOID BETA PROTEIN[1-42]; CD68 ANTIGEN; DENDRITIC CELL VACCINE; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2A; IMMUNOGLOBULIN G2B; AMYLOID BETA PROTEIN; AMYLOID BETA-PROTEIN (1-42); PEPTIDE FRAGMENT;

ALZHEIMER DISEASE; AMYLOID PLAQUE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE MARROW DERIVED DENDRITIC CELL; BRAIN REGION; CELL COUNT; CELL TRANSPLANTATION; CONTROLLED STUDY; DISEASE MODEL; IMMUNOTHERAPY; MEMORY CONSOLIDATION; MICROGLIA; MOUSE; NONHUMAN; PHAGOCYTOSIS; SPATIAL LEARNING; SPLEEN CELL; SPLEEN CELL TRANSPLANTATION; TRANSGENIC MOUSE; TREATMENT OUTCOME; AGING; ANIMAL; BONE MARROW CELL; BRAIN; CYTOLOGY; DENDRITIC CELL; IMMUNOLOGY; INTRAPERITONEAL DRUG ADMINISTRATION; METABOLISM; PROCEDURES; PSYCHOLOGY; SPLEEN; TRANSPLANTATION;

AGING; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; BONE MARROW CELLS; BRAIN; DENDRITIC CELLS; IMMUNOTHERAPY; INJECTIONS, INTRAPERITONEAL; MICE; MICE, TRANSGENIC; MICROGLIA; PEPTIDE FRAGMENTS; PHAGOCYTOSIS; PLAQUE, AMYLOID; SPLEEN;

EID: 84920593748     PISSN: 01974580     EISSN: 15581497     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2014.06.029     Document Type: Article

References (57)

1. Agarwal S., Busse P.J. Innate and adaptive immunosenescence. Ann. Allergy Asthma Immunol. 2010, 104:183-190. quiz 190-182, 210.
2. Bard F., Cannon C., Barbour R., Burke R.L., Games D., Grajeda H., Guido T., Hu K., Huang J., Johnson-Wood K., Khan K., Kholodenko D., Lee M., Lieberburg I., Motter R., Nguyen M., Soriano F., Vasquez N., Weiss K., Welch B., Seubert P., Schenk D., Yednock T. Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat. Med. 2000, 6:916-919.
3. Bayer A.J., Bullock R., Jones R.W., Wilkinson D., Paterson K.R., Jenkins L., Millais S.B., Donoghue S. Evaluation of the safety and immunogenicity of synthetic Abeta42 (AN1792) in patients with AD. Neurology 2005, 64:94-101.
4. Billings L.M., Oddo S., Green K.N., McGaugh J.L., LaFerla F.M. Intraneuronal Abeta causes the onset of early Alzheimer's disease-related cognitive deficits in transgenic mice. Neuron 2005, 45:675-688.
5. Buckwalter M.S., Coleman B.S., Buttini M., Barbour R., Schenk D., Games D., Seubert P., Wyss-Coray T. Increased T cell recruitment to the CNS after amyloid beta 1-42 immunization in Alzheimer's mice overproducing transforming growth factor-beta 1. J.Neurosci. 2006, 26:11437-11441.
6. Busse P.J., Mathur S.K. Age-related changes in immune function: effect on airway inflammation. J.Allergy Clin. Immunol. 2010, 126:690-699. quiz 700-691.
7. Butovsky O., Koronyo-Hamaoui M., Kunis G., Ophir E., Landa G., Cohen H., Schwartz M. Glatiramer acetate fights against Alzheimer's disease by inducing dendritic-like microglia expressing insulin-like growth factor 1. Proc. Natl. Acad. Sci. U.S.A 2006, 103:11784-11789.
8. Cao C.H., Lin X.Y., Zhang C., Wahi M.M., Wefes I., Arendash G., Potter H. Mutant amyloid-beta-sensitized dendritic cells as Alzheimer's disease vaccine. J.Neuroimmunol. 2008, 200:1-10.
9. Cao C., Arendash G.W., Dickson A., Mamcarz M.B., Lin X., Ethell D.W. Abeta-specific Th2 cells provide cognitive and pathological benefits to Alzheimer's mice without infiltrating the CNS. Neurobiol. Dis. 2009, 34:63-70.
10. Chen G., Chen K.S., Kobayashi D., Barbour R., Motter R., Games D., Martin S.J., Morris R.G. Active beta-amyloid immunization restores spatial learning in PDAPP mice displaying very low levels of beta-amyloid. J.Neurosci. 2007, 27:2654-2662.
11. Ethell D.W., Shippy D., Cao C., Cracchiolo J.R., Runfeldt M., Blake B., Arendash G.W. Abeta-specific T-cells reverse cognitive decline and synaptic loss in Alzheimer's mice. Neurobiol. Dis. 2006, 23:351-361.
12. Fang F., Lue L.F., Yan S., Xu H., Luddy J.S., Chen D., Walker D.G., Stern D.M., Schmidt A.M., Chen J.X., Yan S.S. RAGE-dependent signaling in microglia contributes to neuroinflammation, Abeta accumulation, and impaired learning/memory in a mouse model of Alzheimer's disease. FASEB J. 2010, 24:1043-1055.
13. Filali M., Lalonde R., Rivest S. Anomalies in social behaviors and exploratory activities in an APPswe/PS1 mouse model of Alzheimer's disease. Physiol. Behav. 2011, 104:880-885.
14. Fisher Y., Nemirovsky A., Baron R., Monsonego A. Tcells specifically targeted to amyloid plaques enhance plaque clearance in a mouse model of Alzheimer's disease. PLoS One 2010, 5:e10830.
15. Freir D.B., Fedriani R., Scully D., Smith I.M., Selkoe D.J., Walsh D.M., Regan C.M. Abeta oligomers inhibit synapse remodelling necessary for memory consolidation. Neurobiol. Aging 2011, 32:2211-2218.
16. Fuhrmann M., Bittner T., Jung C.K., Burgold S., Page R.M., Mitteregger G., Haass C., LaFerla F.M., Kretzschmar H., Herms J. Microglial Cx3cr1 knockout prevents neuron loss in a mouse model of Alzheimer's disease. Nat. Neurosci. 2010, 13:411-413.
17. Griciuc A., Serrano-Pozo A., Parrado A.R., Lesinski A.N., Asselin C.N., Mullin K., Hooli B., Choi S.H., Hyman B.T., Tanzi R.E. Alzheimer's disease risk gene CD33 inhibits microglial uptake of amyloid beta. Neuron 2013, 78:631-643.
18. Haberthur K., Engelman F., Barron A., Messaoudi I. Immune senescence in aged nonhuman primates. Exp. Gerontol. 2010, 45:655-661.
19. Halle A., Hornung V., Petzold G.C., Stewart C.R., Monks B.G., Reinheckel T., Fitzgerald K.A., Latz E., Moore K.J., Golenbock D.T. The NALP3 inflammasome is involved in the innate immune response to amyloid-beta. Nat. Immunol. 2008, 9:857-865.
20. Hawkes C.A., McLaurin J. Selective targeting of perivascular macrophages for clearance of beta-amyloid in cerebral amyloid angiopathy. Proc. Natl. Acad. Sci. U.S.A 2009, 106:1261-1266.
21. Hickman S.E., Allison E.K., El Khoury J. Microglial dysfunction and defective beta-amyloid clearance pathways in aging Alzheimer's disease mice. J.Neurosci. 2008, 28:8354-8360.
22. Holmes A., Yang R.J., Crawley J.N. Evaluation of an anxiety-related phenotype in galanin overexpressing transgenic mice. J.Mol. Neurosci. 2002, 18:151-165.
23. Holmes C., Boche D., Wilkinson D., Yadegarfar G., Hopkins V., Bayer A., Jones R.W., Bullock R., Love S., Neal J.W., Zotova E., Nicoll J.A. Long-term effects of Abeta42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial. Lancet 2008, 372:216-223.
24. Izquierdo I., Barros D.M., Mello e Souza T., de Souza M.M., Izquierdo L.A., Medina J.H. Mechanisms for memory types differ. Nature 1998, 393:635-636.
25. Jana A., Pahan K. Fibrillar amyloid-beta-activated human astroglia kill primary human neurons via neutral sphingomyelinase: implications for Alzheimer's disease. J.Neurosci. 2010, 30:12676-12689.
26. Janus C., Pearson J., McLaurin J., Mathews P.M., Jiang Y., Schmidt S.D., Chishti M.A., Horne P., Heslin D., French J., Mount H.T., Nixon R.A., Mercken M., Bergeron C., Fraser P.E., St George-Hyslop P., Westaway D. Abeta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. Nature 2000, 408:979-982.
27. Katsimpardi L., Litterman N.K., Schein P.A., Miller C.M., Loffredo F.S., Wojtkiewicz G.R., Chen J.W., Lee R.T., Wagers A.J., Rubin L.L. Vascular and neurogenic rejuvenation of the aging mouse brain by young systemic factors. Science 2014, 344:630-634.
28. Kawarabayashi T., Younkin L.H., Saido T.C., Shoji M., Ashe K.H., Younkin S.G. Age-dependent changes in brain, CSF, and plasma amyloid (beta) protein in the Tg2576 transgenic mouse model of Alzheimer's disease. J.Neurosci. 2001, 21:372-381.
29. Kipnis J., Cohen H., Cardon M., Ziv Y., Schwartz M. Tcell deficiency leads to cognitive dysfunction: implications for therapeutic vaccination for schizophrenia and other psychiatric conditions. Proc. Natl. Acad. Sci. U.S.A 2004, 101:8180-8185.
30. Koffie R.M., Meyer-Luehmann M., Hashimoto T., Adams K.W., Mielke M.L., Garcia-Alloza M., Micheva K.D., Smith S.J., Kim M.L., Lee V.M., Hyman B.T., Spires-Jones T.L. Oligomeric amyloid beta associates with postsynaptic densities and correlates with excitatory synapse loss near senile plaques. Proc. Natl. Acad. Sci. U.S.A 2009, 106:4012-4017.
31. Kummer M.P., Vogl T., Axt D., Griep A., Vieira-Saecker A., Jessen F., Gelpi E., Roth J., Heneka M.T. Mrp14 deficiency ameliorates amyloid beta burden by increasing microglial phagocytosis and modulation of amyloid precursor protein processing. J.Neurosci. 2012, 32:17824-17829.
32. Li S., Hong S., Shepardson N.E., Walsh D.M., Shankar G.M., Selkoe D. Soluble oligomers of amyloid beta protein facilitate hippocampal long-term depression by disrupting neuronal glutamate uptake. Neuron 2009, 62:788-801.
33. Liu Y.H., Giunta B., Zhou H.D., Tan J., Wang Y.J. Immunotherapy for Alzheimer disease: the challenge of adverse effects. Nat. Rev. Neurol. 2012, 8:465-469.
34. Mandrekar S., Jiang Q., Lee C.Y., Koenigsknecht-Talboo J., Holtzman D.M., Landreth G.E. Microglia mediate the clearance of soluble Abeta through fluid phase macropinocytosis. J.Neurosci. 2009, 29:4252-4262.
35. McGowan E., Pickford F., Kim J., Onstead L., Eriksen J., Yu C., Skipper L., Murphy M.P., Beard J., Das P., Jansen K., Delucia M., Lin W.L., Dolios G., Wang R., Eckman C.B., Dickson D.W., Hutton M., Hardy J., Golde T. Abeta42 is essential for parenchymal and vascular amyloid deposition in mice. Neuron 2005, 47:191-199.
36. McLaurin J., Cecal R., Kierstead M.E., Tian X., Phinney A.L., Manea M., French J.E., Lambermon M.H., Darabie A.A., Brown M.E., Janus C., Chishti M.A., Horne P., Westaway D., Fraser P.E., Mount H.T., Przybylski M., St George-Hyslop P. Therapeutically effective antibodies against amyloid-beta peptide target amyloid-beta residues 4-10 and inhibit cytotoxicity and fibrillogenesis. Nat. Med. 2002, 8:1263-1269.
37. Moalem G., Leibowitz-Amit R., Yoles E., Mor F., Cohen I.R., Schwartz M. Autoimmune T cells protect neurons from secondary degeneration after central nervous system axotomy. Nat. Med. 1999, 5:49-55.
38. Morgan D., Diamond D.M., Gottschall P.E., Ugen K.E., Dickey C., Hardy J., Duff K., Jantzen P., DiCarlo G., Wilcock D., Connor K., Hatcher J., Hope C., Gordon M., Arendash G.W. Abeta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature 2000, 408:982-985.
39. Nabar N.R., Yuan F., Lin X., Wang L., Bai G., Mayl J., Li Y., Zhou S.F., Wang J., Cai J., Cao C. Cell therapy: a safe and efficacious therapeutic treatment for Alzheimer's disease in APP+PS1 mice. PLoS One 2012, 7:e49468.
40. Nicoll J.A., Wilkinson D., Holmes C., Steart P., Markham H., Weller R.O. Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report. Nat. Med. 2003, 9:448-452.
41. Park L., Zhou J., Zhou P., Pistick R., El Jamal S., Younkin L., Pierce J., Arreguin A., Anrather J., Younkin S.G., Carlson G.A., McEwen B.S., Iadecola C. Innate immunity receptor CD36 promotes cerebral amyloid angiopathy. Proc. Natl. Acad. Sci. U.S.A 2013, 110:3089-3094.
42. Pfeifer M., Boncristiano S., Bondolfi L., Stalder A., Deller T., Staufenbiel M., Mathews P.M., Jucker M. Cerebral hemorrhage after passive anti-Abeta immunotherapy. Science 2002, 298:1379.
43. Reed-Geaghan E.G., Reed Q.W., Cramer P.E., Landreth G.E. Deletion of CD14 attenuates Alzheimer's disease pathology by influencing the brain's inflammatory milieu. J.Neurosci. 2010, 30:15369-15373.
44. Richartz E., Stransky E., Batra A., Simon P., Lewczuk P., Buchkremer G., Bartels M., Schott K. Decline of immune responsiveness: a pathogenetic factor in Alzheimer's disease?. J.Psychiatr. Res. 2005, 39:535-543.
45. Rolls A., Shechter R., London A., Ziv Y., Ronen A., Levy R., Schwartz M. Toll-like receptors modulate adult hippocampal neurogenesis. Nat. Cell Biol. 2007, 9:1081-1088.
46. Ron-Harel N., Segev Y., Lewitus G.M., Cardon M., Ziv Y., Netanely D., Jacob-Hirsch J., Amariglio N., Rechavi G., Domany E., Schwartz M. Age-dependent spatial memory loss can be partially restored by immune activation. Rejuvenation Res. 2008, 11:903-913.
47. Schenk D., Barbour R., Dunn W., Gordon G., Grajeda H., Guido T., Hu K., Huang J., Johnson-Wood K., Khan K., Kholodenko D., Lee M., Liao Z., Lieberburg I., Motter R., Mutter L., Soriano F., Shopp G., Vasquez N., Vandevert C., Walker S., Wogulis M., Yednock T., Games D., Seubert P. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 1999, 400:173-177.
48. Simard A.R., Soulet D., Gowing G., Julien J.P., Rivest S. Bone marrow-derived microglia play a critical role in restricting senile plaque formation in Alzheimer's disease. Neuron 2006, 49:489-502.
49. Streit W.J., Xue Q.S. Alzheimer's disease, neuroprotection, and CNS immunosenescence. Front. Pharmacol. 2012, 3:138.
50. Um J.W., Nygaard H.B., Heiss J.K., Kostylev M.A., Stagi M., Vortmeyer A., Wisniewski T., Gunther E.C., Strittmatter S.M. Alzheimer amyloid-beta oligomer bound to postsynaptic prion protein activates Fyn to impair neurons. Nat. Neurosci. 2012, 15:1227-1235.
51. Urbanc B., Cruz L., Le R., Sanders J., Ashe K.H., Duff K., Stanley H.E., Irizarry M.C., Hyman B.T. Neurotoxic effects of thioflavin S-positive amyloid deposits in transgenic mice and Alzheimer's disease. Proc. Natl. Acad. Sci. U.S.A 2002, 99:13990-13995.
52. Villeda S.A., Luo J., Mosher K.I., Zou B., Britschgi M., Bieri G., Stan T.M., Fainberg N., Ding Z., Eggel A., Lucin K.M., Czirr E., Park J.S., Couillard-Després S., Aigner L., Li G., Peskind E.R., Kaye J.A., Quinn J.F., Galasko D.R., Xie X.S., Rando T.A., Wyss-Coray T. The ageing systemic milieu negatively regulates neurogenesis and cognitive function. Nature 2011, 477:90-94.
53. Villeda S.A., Plambeck K.E., Middeldorp J., Castellano J.M., Mosher K.I., Luo J., Smith L.K., Bieri G., Lin K., Berdnik D., Wabl R., Udeochu J., Wheatley E.G., Zou B., Simmons D.A., Xie X.S., Longo F.M., Wyss-Coray T. Young blood reverses age-related impairments in cognitive function and synaptic plasticity in mice. Nat. Med. 2014, 20:659-663.
54. Vom Berg J., Prokop S., Miller K.R., Obst J., Kalin R.E., Lopategui-Cabezas I., Wegner A., Mair F., Schipke C.G., Peters O., Winter Y., Becher B., Heppner F.L. Inhibition of IL-12/IL-23 signaling reduces Alzheimer's disease-like pathology and cognitive decline. Nat. Med. 2012, 18:1812-1819.
55. Wilberding A., Morimoto K., Satoh H., Harano K., Harano T., Arita S., Tooyama I., Konishi Y. Multiple cytokines are involved in the early events leading to the Alzheimer's disease pathology. Tottori Rinsho Kagaku Kenkyukai Shi. 2008, 1:359-373.
56. Ziv Y., Schwartz M. Immune-based regulation of adult neurogenesis: implications for learning and memory. Brain Behav. Immun. 2008, 22:167-176.
57. Ziv Y., Ron N., Butovsky O., Landa G., Sudai E., Greenberg N., Cohen H., Kipnis J., Schwartz M. Immune cells contribute to the maintenance of neurogenesis and spatial learning abilities in adulthood. Nat. Neurosci. 2006, 9:268-275.